Saad Usmani to Standard of Care
This is a "connection" page, showing publications Saad Usmani has written about Standard of Care.
Connection Strength
0.436
-
Korde N, Usmani SZ. Cross Fire: Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma. Hematol Oncol Stem Cell Ther. 2023 01 17; 16(2):117-123.
Score: 0.193
-
Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 2022 Apr; 82(6):613-631.
Score: 0.183
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
Score: 0.060